Obsidian is proud to collaborate with Bristol Myers Squibb (via acquisition of Celgene) in the discovery and development of novel, regulated cell therapies that utilize Obsidian’s cytoDRiVE™ technology. Our collaboration is focused on two specific immunomodulatory factors, IL12 and CD40L, which require precise control to optimize their therapeutic benefit. This multi-year collaboration provides BMS with the exclusive option to in-license worldwide rights for cell therapy candidates that incorporate regulated IL12 or CD40L for the treatment of cancer. The collaboration includes an upfront payment and equity investment by BMS, and potential future milestone and royalty payments.
“Obsidian’s technology has the potential to unlock the activity of cell therapy in a number of new settings, particularly against solid tumor malignancies… We value the innovation that the Obsidian team can bring and we look forward to working together to bring powerful new immunotherapies to patients.”
Robert Hershberg, M.D., Ph.D.
Executive Vice President, Business Development & Global Alliances for Celgene Corporation